Infect Control Hosp Epidemiol . National survey study of nirmatrelvir-ritonavir prescribing processes and access barriers during the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) omicron surge of the coronavirus disease 2019...

[tetano]

Infect Control Hosp Epidemiol


. 2023 Apr 20;1-3.
doi: 10.1017/ice.2023.71. Online ahead of print.
National survey study of nirmatrelvir-ritonavir prescribing processes and access barriers during the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) omicron surge of the coronavirus disease 2019 (COVID-19) pandemic


Rebecca Wang ¹ , Michael S Calderwood ¹ , Craig P Worby ² , Jose R Mercado ³ , Justin J Kim ¹



Affiliations

• PMID: 37078462
• DOI: 10.1017/ice.2023.71

Abstract

In this national survey, we found that individual patient assessments by pharmacists were more common at facilities using centralized prescribing for nirmetralvir-ritonavir (Paxlovid) than decentralized prescribing. Provider discomfort was initially less with centralized prescribing, but later, there was no difference in provider discomfort based on prescribing mechanism.